Trial Profile
A 52 Week Open Label Extension Study to Evaluate the Safety and Tolerability of AIN457 (Anti IL-17 Monoclonal Antibody) in Patients With Moderate to Severe Crohn's Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Crohn's disease; Various toxicities
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Sponsors Novartis
- 30 Mar 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov
- 30 Mar 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov
- 17 May 2012 Primary endpoint 'Crohn's-Disease-Activity-Index' has not been met according to results presented in Gut.